A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma

Trial Profile

A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 1 Jun 2018 to 30 Jun 2018.
    • 21 Dec 2015 Results published in the Celgene International SARL media release.
    • 21 Dec 2015 According to a Celgene International SARL media release, the Japan's Ministry of Health, Labour and Welfare (MHLW) has granted full marketing authorization to lenalidomide (Revlimid) in combination with dexamethasone for treatment of newly diagnosed multiple myeloma patients. The approval was based on results from this and the global phase III FIRST trial (CTP 700033737).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top